Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease

NCT ID: NCT00770575

Last Updated: 2010-07-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 148 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-06-30
• Study Completion Date: 2006-10-31

Brief Summary

The purpose of this study is to determine the effect of pioglitazone, once daily (QD), and atorvastatin combination therapy compared to atorvastatin monotherapy in patients at risk for cardiovascular disease.

Detailed Description

Carotid intima-media thickness is a well described surrogate marker for cardiovascular risk. A thickened carotid intima media layer correlates not only with the presence of cardiovascular risk factors but also the risk of future macrovascular events such as myocardial infarction and stroke. The interventional approach of cardiovascular risk factors with angiotensin converting enzyme system blockers, calcium antagonists or beta blockers can result in reduction of progression or even net regression of carotid intima-media thickness. The most potent agents, however, are statins which have consistently shown effects on carotid intima-media thickness in patients with hypercholesterolemia and/or atherosclerotic disease.

Peroxisome proliferator activator receptor-gamma activation by thiazolidinediones is a promising new approach which reduces insulin resistance and improves lipid profile. In addition to their metabolic activities, peroxisome proliferator activator receptor-gamma activators were shown to exert anti-inflammatory effects, to improve endothelial function and to inhibit atherogenesis in diabetic and in non-diabetic atherosclerosis-prone animal models. Treatment with peroxisome proliferator activator receptor-gamma agonists have shown to reduce arterial pressure and carotid intima-media thickness in diabetic and non-diabetic patients at risk for cardiovascular disease.

The aim of this study is to evaluate the effect of Pioglitazone in addition to Atorvastatin compared to Atorvastatin alone on vascular risk markers and intima-media thickness in patients with elevated risk for cardiovascular disease.

Conditions

Cardiovascular Diseases

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Pioglitazone 30mg to 45 mg QD + Atorvastatin 20 mg to 40 mg QD

Group Type: EXPERIMENTAL

Pioglitazone and atorvastatin

Intervention Type: DRUG

Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to:

Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks.

Atorvastatin 20mg to 40 mg QD

Group Type: ACTIVE_COMPARATOR

Atorvastatin

Intervention Type: DRUG

Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to

Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks.

Interventions

Pioglitazone and atorvastatin

Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to:

Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks.

Intervention Type: DRUG

Atorvastatin

Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to

Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks.

Intervention Type: DRUG

Other Intervention Names

ACTOS®; AD4833

Eligibility Criteria

Inclusion Criteria

• Intima-media thickness of Common Carotid Artery greater than or equal to 0.8 mm (at least on one side).
• Increased cardiovascular risk defined as one or more of the following:

• medical history of infarction
• coronary angiography with proven cardiovascular disease
• instable Angina pectoris
• duplex-sonography of cervical or leg vessels with proven atherosclerotic vascular alterations
• electrocardiogram with ischemia
• stroke
• transient ischemic attack
• peripheral arterial occlusion
• vessel surgery
• hypertension (RR greater than 140/90)
• antihypertensives
• high density lipoprotein less than 40 mg/dl.
• Body mass index greater than or equal to 25 kg/m2.
• Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.

Exclusion Criteria

• History of overt type-2-diabetes according to the World Health Organization criteria.
• History of type-1-diabetes.
• History of more than one unexplained hypoglycemic episode within the last 6 months.
• Statin therapy within the last 4 weeks.
• Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures.
• History of severe or multiple allergies.
• Treatment with any other investigational drug within 3 months before trial entry.
• Progressive fatal disease.
• Myopathy.
• Drug or alcohol abuse within the last 5 years.
• Smoker defined as patient with evidence or history of tobacco or nicotine use within the last 6 months before the screening visit.
• A history of heart failure (New York Heart Association stage II - IV) or significant respiratory, gastrointestinal, hepatic (glutamate-pyruvate-transaminase time greater than 2.5 times the normal reference range), renal (creatinine greater than 2.0 mg/dl) or hematological disease.
• Blood donation within the last 30 days.
• Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

• ciclosporin
• erythromycin
• clarithromycin
• itraconazole
• ketoconazole
• nefazodone
• niacin
• gemfibrozil and other fibrates
• HIV-Protease-Inhibitors
• Pre-treatment with thiazolidinediones within 3 months before trial entry.

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Takeda

INDUSTRY

Sponsor Role: lead

Responsible Party

Takeda Pharma GmbH, Aachen (Germany)

Principal Investigators

Head of Clinical Research/Licensing/New Products

Role: STUDY_DIRECTOR

Takeda Pharma Gmbh, Aachen (Germany)

Related Links

http://general.takedapharm.com/content/file/pi.pdf?applicationcode=ab2d7112-8eb3-465a-8fda-35018a9eafb0&fileTypeCode=ACTOSPI

ACTOS® Package Insert

Other Identifiers

2004-004463-30

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

D-PIO-106

Identifier Type: OTHER

Identifier Source: secondary_id

U1111-1115-9124

Identifier Type: REGISTRY

Identifier Source: secondary_id

ATS K015

Identifier Type: -

Identifier Source: org_study_id